Publications: MISS Christine Hughes

Guo Q, Househam J, Lakatos E, Nowinski S, Al Bakir I, Grant H, Balarajah V, Hughes CS et al. ( 2024 ) . Long deletion signatures in repetitive genomic regions track somatic evolution and enable sensitive detection of microsatellite instability .

Oscanoa J, Ross-Adams H, Dayem Ullah AZM, Kolvekar TS, Sivapalan L, Gadaleta E, Thorn GJ, Abdollahyan M et al. ( 2024 ) . A central research portal for mining pancreatic clinical and molecular datasets and accessing biobanked samples .

Nowinski S, Balarajah V, Baker A-M, Katainen R, Hughes C, Guo Q, Zapata L, Lakatos E et al. ( 2024 ) . Abstract B011: Lower incidence of small intestinal adenocarcinomas may be due to constrained copy number karyotype and increased immune surveillance . Cancer Research vol. 84 , ( 3_Supplement_2 ) B011 - B011 .

Zardab M, Balarajah V, Banerjee A, Stasinos K, Saad A, Imrali A, Hughes C, Roberts R et al. ( 2022 ) . Differentiating Ductal Adenocarcinoma of the Pancreas from Benign Conditions Using Routine Health Records: A Prospective Case-Control Study . Cancers vol. 15 , ( 1 ) 280 - 280 .

Zardab M, Balarajah V, Banerjee A, Stasinos K, Saad A, Imrali A, Hughes C, Roberts R et al. ( 2022 ) . Development of a Model for Differentiating PDAC from Benign Pancreatic Conditions: A Prospective Case-control Study .

Goulart MR, Watt J, Siddiqui I, Lawlor RT, Imrali A, Hughes C, Saad A, ChinAleong J et al. ( 2021 ) . Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinoma . npj Precision Oncology vol. 5 , ( 1 ) Article 61 ,

Kocher HM, Basu B, Froeling FEM, Sarker D, Slater S, Carlin D, deSouza NM, De Paepe KN et al. ( 2020 ) . STARPAC clinical trial . Pancreatology vol. 20 , ( 8 ) e17 - e17 .

Imrali A, Hughes CS, Coetzee AS, Delvecchio FR, Saad A, Roberts R, Chelala C, ChinAleong J et al. ( 2020 ) . Validation of a Novel, Flash‐Freezing Method: Aluminum Platform . Current Protocols Essential Laboratory Techniques vol. 21 , ( 1 ) Article e46 ,

Kocher HM, Basu B, Froeling FEM, Sarker D, Slater S, Carlin D, deSouza NM, De Paepe KN et al. ( 2020 ) . Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer . Nature Communications vol. 11 , ( 1 ) Article 4841 ,

Hughes CS, ChinAleong J-A, Kocher HM ( 2020 ) . CRABP2 and FABP5 expression levels in diseased and normal pancreas . Annals of Diagnostic Pathology vol. 47 , Article 151557 , 151557 - 151557 .

Kocher HM, Basu B, Froeling FEM, Sarker D, Slater S, Carlin D, Coetzee C, de Souza N et al. ( 2019 ) . STAR-PAC: Phase I clinical trial repurposing all trans retinoic acid (ATRA) as stromal targeting agent in a novel drug combination for pancreatic cancer . Annals of Oncology vol. 30 , v267 - v267 .